FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

Device Computational Modeling Credibility Guide

FDA publishes a guidance to help in assessing the credibility of computational modeling and simulation in medical device submissions.

latest-news-card-1
Human Drugs

U.S. Drug Shortages Increasing: Report

An Iqvia Institute report says drug shortages continue to increase in the U.S., with the number of new shortages outpacing the number resolved.

latest-news-card-1
Human Drugs

Provide Covid Therapeutics Distribution Info: Califf

FDA commissioner Robert Califf calls on the Healthcare Distribution Alliance to give aggregate information to the agency on the distribution of Covid ...

FDA General

2 Consent Decrees Against Supplement Marketers

The central Utah federal court approves two consent decrees of permanent injunction against Evig LLC and Premium Production LLC over their distributio...

Human Drugs

SpringWorks Filing Mirdametinib NDA in 2024

After releasing promising clinical data, SpringWorks Therapeutics says it will file an NDA in the first half of 2024 for mirdametinib, an investigatio...

latest-news-card-1
Human Drugs

Janet Woodcock Retiring in Early 2024

FDA principal deputy commissioner Janet Woodcock announces she is retiring early next year after 37 years at the agency.

latest-news-card-1
Medical Devices

Managing Legacy Device Cyber Risks

An FDA-funded report makes recommendations for improving the cybersecurity of legacy medical devices.

latest-news-card-1
Human Drugs

BMS Gains Approval for Lung Cancer NDA

FDA approves a Bristol Myers Squibb NDA for Augtyro (repotrectinib) for treating adult patients with locally advanced or metastatic ROS1-positive non-...

latest-news-card-1
Medical Devices

IceCure Medical Appeals De Novo Denial

Israels IceCure Medical says it is appealing an FDA denial of the companys de novo classification request for its ProSense cryoablation system for use...

latest-news-card-1
Human Drugs

Ascendis Pharma Refiles NDA on TransCon PTH

Ascendis Pharma resubmits an NDA for TransCon PTH (palopegteriparatide) for treating adults with hypoparathyroidism.